Greenwood, SC (USA), 7 November 2018 – Lonza has announced its Capsugel® DRcaps™ capsules have been verified as non-GMO by the Non-GMO Project organization. DRcaps™ capsules are designed to help protect sensitive ingredients, such as probiotics, from stomach acid, as well as to provide taste and odor masking and to reduce bad aftertastes. Completing the company’s unrivalled Non-GMO Project Verified vegetarian hard capsule portfolio, the latest verification offers further clean-label options for supplement manufacturers, as well as greater transparency and additional natural choices for consumers.
Generally regarded as a global quality seal, the Non-GMO Project organization provides North America’s only independent verification for products made according to best practices for GMO avoidance. Manufactured at Lonza’s Greenwood site in South Carolina, DRcaps™ capsules join Lonza’s comprehensive range of Non-GMO Verified vegetarian and vegan options, including Vcaps® and Vcaps® Plus capsules, which are made from hypromellose (HPMC) and water, and Plantcaps® pullulan capsules.
“Plant-based, clean-label dosage forms are a vital component to support claims on supplement labels and ultimately meet consumer preferences for more-natural products," said Karin Schrooten, Quality Director at Lonza Consumer Health & Nutrition. "As one of the first companies with liquid-filled and empty capsules to be verified by the Non-GMO Project organization, we were first verified in 2013 for our Vcaps® Plus vegetarian capsules. Carrying this pioneering spirit through to today’s announcement, we now have one of the most comprehensive non-GMO, vegan and clean-label hard capsule portfolios on the market.”
She added: “The Non-GMO Project Verified seal is the most trusted non-GMO label among consumers. It offers assurance to shoppers across the world that a product has completed a thorough third-party process for compliance with the Non-GMO Project Standard.”
More information about DRcaps™ capsules or Lonza’s non-GMO and clean label hard capsule range is available on the DRcaps™ capsules page.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.